SS Innovations (Nasdaq: SSII) showcases advanced surgical robotics at SMRSC 2026
Rhea-AI Filing Summary
SS Innovations International, Inc. filed an 8-K to share a press release about its vision for new surgical robotic technologies unveiled at the Global Multi-Specialty Robotic Surgery Conference (SMRSC 2026) in New Delhi, India, which the Company recently hosted.
The Company highlighted four main innovations under development: the SSi Vimana Aero drone-based surgical system, the SSi Avtara humanoid surgical platform, the SSi Operion mobile operating room, and new single-arm robotic endoscopy and ultrasound assist carts. These concepts emphasize remote, mobile and teleoperated care in challenging environments.
At SMRSC 2026, more than 1,600 in-person and 1,800 virtual participants from 19 nations attended. Expert physicians performed 10 live telesurgeries and 13 live robotic surgeries using the Company’s existing SSi Mantra system across multiple specialties. The filing also reiterates standard forward-looking statement cautions.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
telesurgery medical
humanoid surgical platform medical
forward-looking statements regulatory
teleoperation frameworks technical
multi-arm system medical
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
|
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including
area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As used in this Current Report on Form 8-K (this “Current Report”), the terms “SSi,” “the Company,” “we,” “us” and “our” refer to SS Innovations International, Inc. and its subsidiaries.
Item 7.01 Regulation FD Disclosure.
On April 23, 2026, SSi issued a press release announcing that the Company unveiled its vision for several cutting-edge surgical robotic technologies at the 2026 Global Multi-Specialty Robotic Surgery Conference, (which the Company recently hosted in New Delhi, India.
A copy of the press release is included with this Current Report as Exhibit 99.1.
The information set forth in this Item 7.01 and contained in or linked to the press release included as Exhibit 99.1 to this Current Report, are deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in this Item 7.01 and contained in or linked to the press release included as Exhibit 99.1 to this Current Report, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Forward-Looking Statements
This Current Report and the press release included as Exhibit 99.1 to this Current Report (including information linked to the press release), contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding the Company’s intent, belief or expectations, including, but not limited to, statements regarding the Company’s product developments, clinical and regulatory timelines, market opportunity, competitive position, present possible or assumed future results of operations and other statements that are predictive in nature. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SSi’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1* | Press Release, dated April 23, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| * | Furnished not filed |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: April 23, 2026 | SS INNOVATIONS INTERNATIONAL, INC. | |
| By: | /s/ Sudhir Srivastava | |
| Sudhir Srivastava, M.D. | ||
| Chairman and Chief Executive Officer | ||
2
Exhibit 99.1
SS Innovations Unveils Cutting-Edge Surgical Robotic Technologies at SMRSC 2026
Innovations under development by Company include the SSi Vimana Aero, SSi Avtara and SSi Operion
Fort Lauderdale, FL – April 23, 2026 – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company has unveiled its vision for several cutting-edge surgical robotic technologies at the Global Multi-Specialty Robotic Surgery Conference (“SMRSC 2026”), which the Company recently hosted in New Delhi, India. Key innovations under development by the Company and showcased at SMRSC 2026 include the SSi Vimana Aero Drone System (the “SSi Vimana Aero”), the SSi Avtara Humanoid Surgical Platform (the “SSi Avtara”), the SSi Operion Mobile Operating Room (the “SSi Operion”), and new single-arm robotic endoscopy and ultrasound assist carts.
| The SSi Vimana Aero is a surgical robotic system currently under development and designed to bring expert robotic surgical care directly to wounded soldiers in active battle zones, bridging the critical time gap between initial point of injury and eventual medical evacuation from the frontlines. Deployed via a heavy-lift autonomous drone, the SSi Vimana Aero can land in proximity to the casualty and deploy two miniature robotic arms with seven degrees of freedom. A trauma surgeon then can remotely operate the SSi Vimana Aero, which is equipped with 5-millimeter surgical instruments, through an SSi Mantra surgeon command center. The SSi Vimana Aero platform is intended to address hemorrhaging, wound repair, chest decompression, shrapnel extraction, and field suturing, among other procedures, to help stabilize patients until evacuation teams arrive. |
(Depiction of the SSi Vimana Aero Drone System) | |
The SSi Avtara, another innovation under conceptual development, aims to leverage the advanced mobility, dexterity, and perception capabilities of humanoid systems for high-impact surgical robotic applications spanning healthcare, defense, logistics, disaster response, and industrial settings. Integrated with artificial intelligence, teleoperation frameworks, and real-time sensing, the SSi Avtara will be designed for trainability, continuous learning, adaptability, and precision in the field. From assisting clinical workflows to operating in hazardous or otherwise inaccessible environments, the Company anticipates that the platform's human-compatible design will enable seamless interaction with existing infrastructure and tools.
|
(Depiction of the SSi Avtara Humanoid Robot) |
| The SSi Operion, also currently under development, is a fully mobile, platform-agnostic operating room ecosystem designed for seamless deployment across hospitals, remote locations, combat areas, and disaster zones. The SSi Operion is designed to be built on a wheeled chassis with overhead-integrated robotics and a zero-footprint architecture, which seeks to eliminate conventional spatial constraints by suspending all surgical components from an integrated overhead system, enabling 360-degree clinician access, real-time reconfiguration, and seamless deployment. With integrated telesurgery capabilities and low-latency connectivity, the SSi Operion is expected to enable expert surgeons to operate remotely, expanding access to advanced surgical care across geographies. From defense operations to humanitarian missions and rural healthcare delivery, SS Innovations believes that SSi Operion holds potential to transform the operating room into a deployable, mission-ready asset. |
(Depiction of the SSi Operion Mobile Operating Room) | |
The Company’s new single-arm robotic endoscopy and ultrasound assist carts, currently proceeding through early clinical validation phases in India, are designed to provide stable, precise, and repeatable positioning of endoscopic and ultrasound instruments within clinical environments, bringing robotic consistency to workflows. Operating under direct clinician supervision, the robotic arms incorporate controlled speed, force limits, and predictable motion behavior, ensuring safe interaction with both patients and operators. Compatibility with standard hospital infrastructure and existing clinical workflows allows for seamless integration into established clinical settings. |
(SS Innovations’ single-arm robotic assist cart) |
For a video clip of these and other new advancements underway at SS Innovations, along with the Company’s existing surgical robotic technologies, please visit: https://youtu.be/oO-yoo82pfE.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “Innovation is in our DNA. Beyond continuously improving our advanced, cost-effective SSi Mantra surgical robotic system and telesurgery capabilities, we strive to pioneer new surgical robotic technologies that will meaningfully improve healthcare for a wider segment of patients in need. SMRSC 2026, our largest conference yet, successfully elevated this important theme.”
Recap of SMRSC 2026
SMRSC 2026 brought together distinguished surgeons, global thought leaders, educators, and prominent healthcare innovators to discuss and shape the future of robotic surgery. Attendance at SMRSC 2026 surpassed that of last year’s conference, drawing more than 1,600 attendees and 1,800 virtual participants from 19 nations. In addition to unveiling new surgical robotic technologies and groundbreaking concepts at SMRSC 2026, SS Innovations showcased the SSi Mantra’s capabilities. At the conference, expert physicians conducted 10 live telesurgeries and 13 live robotic surgeries across multiple specialties utilizing the SSi Mantra. The three-day event also featured dozens of panel discussions spanning specialties, including urology, thoracic, gastroenterology, head & neck, gynecology, colorectal, general and pediatric, among others, with separate cardiac-focused breakout sessions. Prominent guests and presenters at this year’s conference included, among others, the Company’s Vice-Chairman, Dr. Fred Moll, who has been widely recognized as the “Father of Robotic Surgery”; Shri Pratap Rao Jadhav, the Minister of State for Health and Family Welfare of India; Sri Madhusudan Sai, a global humanitarian and founder of a worldwide free healthcare mission; and Dr. Mylswamy Annadurai, Former Director, ISRO Satellite Center.
2
About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.
About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana Tele Surgeon Console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that provides equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.
Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Investor Contact:
The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kahl@theequitygroup.com
Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@theequitygroup.com
Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com
3